Literature DB >> 7784012

Good practice with endometrial ablation.

R Garry1.   

Abstract

OBJECTIVE: To provide clear guidelines for the safe and effective performance of endometrial ablation. DATA SOURCES: Representatives of American, Australian, British, and Canadian hysteroscopists were brought together to produce a consensus document of good practice in endometrial ablation. METHODS OF STUDY SELECTION: The guidelines were produced after researching the literature, combining the extensive experience of the group, and debating the relevant issues.
CONCLUSIONS: Endometrial ablation is a new procedure. Correct patient selection is essential in producing good results. Patients must be counseled carefully about the advantages, disadvantages, and potential complications of this approach to the management of menstrual disorders. The main indication for endometrial ablation is heavy menstrual loss in the absence of organic disease. Excessive uterine size, the presence of active pelvic infection, and evidence of malignant and premalignant endometrium are absolute contraindications. Ablation can be produced by electrosurgical resection, rollerball or rollerbarrel ablation and Nd-YAG laser ablation. Severe complications can occur, and techniques should be adopted to avoid uterine perforation, hemorrhage, and excessive fluid absorption. In skilled hands, endometrial ablation can be a safe and effective treatment for menorrhagia.

Entities:  

Mesh:

Year:  1995        PMID: 7784012     DOI: 10.1016/0029-7844(95)99210-Y

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

1.  Combining myoma coagulation with endometrial ablation/resection reduces subsequent surgery rates.

Authors:  H A Goldfarb
Journal:  JSLS       Date:  1999 Oct-Dec       Impact factor: 2.172

2.  Trans-cervical resection of the endometrium: the first four years' experience at the Belfast City Hospital.

Authors:  D C Hunter; H R McClelland
Journal:  Ulster Med J       Date:  1998-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.